Colorectal Cancer

CheckMate 142 Update: Prolonged Disease Control With Nivolumab in Deficient Mismatch Repair Colorectal Cancer

With 6 additional months of follow-up since the initial presentation of results, in the phase II CheckMate 142 trial, 74% of heavily pretreated patients with metastatic colorectal...

Pain Management

Combating Untreated Cancer-Related Pain

The problem of pain management facing clinicians today is twofold: how to ensure safe and effective treatment for patients with cancer in chronic pain...

Issues in Oncology
Cost of Care

Timing Is Everything

In 1959, my 5-year-old cousin, Kim, was diagnosed with acute lymphocytic leukemia (ALL). As an 8-year-old, I didn’t really understand what was happening to him...


More Top Stories

Solid Tumors

Mohammad Abu Zaid, MD, on Testicular Cancer: Study Results on Metabolic Syndrome

Health-Care Policy

Oncology Drug Approvals in 2016

In 2016, the Office of Hematology and Oncology Products of the U.S. Food and Drug Administration (FDA) approved a number of new molecular entities, indications, and tests. The most notable were drug approvals in disease areas such as non–small cell lung cancer, myeloma, head and neck cancer, and...


Study Finds Cancer Mortality in Hispanics Varies Among Ethnic Groups

Although cancer is a leading cause of death among Hispanics, the burden of cancer mortality within Hispanic groups has not been well quantified. Now, a study by Pinheiro et al comparing the differences among Hispanic populations and cancer incidence has found that cancer mortality varies...

Kidney Cancer

Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results

Neuroendocrine Tumors

Telotristat Ethyl Reduces Frequency of Bowel Movements in Patients With Metastatic Neuroendocrine Tumors and Carcinoid Syndrome

In the phase III TELESTAR trial reported in the Journal of Clinical ­Oncology by Matthew H. Kulke, MD, of Dana-Farber Cancer Institute, and colleagues, telotristat ethyl, an investigational tryptophan hydroxylase inhibitor, significantly reduced the frequency of bowel movements in patients with...

Conquer Cancer Foundation Hosts Successful Scientific and Career Development Retreat

In October 2016, the Conquer Cancer Foundation of ASCO (CCF) hosted its Second Scientific and Career Development Retreat at ASCO headquarters in Alexandria, Virginia. Attendees included Career Development Award (CDA) and Young Investigator Award (YIA) recipients awarded between 2010 and 2016;...

Myeloablative vs Reduced-Intensity HCT for Acute Myeloid Leukemia and Myelodysplastic Syndromes

In a phase III trial reported in the Journal of Clinical Oncology, Scott et al found that myeloablative conditioning for allogeneic hematopoietic cell transplantation was associated with a reduced risk of relapse and a nonsignificant overall survival advantage vs reduced-intensity conditioning in...

Gastroesophageal Cancer

Geoffrey Ku, MD, MBA, on Gastric and Esophageal Cancers: Expert Perspectives on Immunotherapy

Breast Cancer

Novel Antibody-Drug Conjugate Targets Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab govitecan (IMMU-132) produced high objective response rates, many of them quite durable, in a multicenter study of heavily pretreated patients with metastatic triple-negative breast cancer, presented at the 2016 San Antonio Breast Cancer Symposium.1



FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. The expanded indication makes...

click me